The macrophage activation marker sCD163 combined with markers of the Enhanced Liver Fibrosis (ELF) score predicts clinically significant portal hypertension in patients with cirrhosis
T D Sandahl, R McGrail, H J Møller, E Reverter, Søren Møller, F Turon, V Hernández-Gea, F Bendtsen, H Vilstrup, J C Garcia-Pagan, H. Grønbæk
Dive into the research topics of 'The macrophage activation marker sCD163 combined with markers of the Enhanced Liver Fibrosis (ELF) score predicts clinically significant portal hypertension in patients with cirrhosis'. Together they form a unique fingerprint.